Concessionary prices will be paid against the usual code, no additional endorsements are needed.
Please continue to notify CPNI of any pricing issues you are experiencing via our new Medicine Shortage Reporter.
Concessionary prices are also published on the CPNI website.
Kind regards
SENT ON BEHALF OF GERARD GREENE
Chief Executive
Dear Contractor
The Department of Health and Social Care (DHSC) has issued a further five Serious Shortage Protocols (SSPs) (SSP043 – SSP047) in response to current concerns across the UK regarding the availability of antibiotic preparations required for the treatment of Group A Streptococcus infection. These SSPs, which are detailed in the attached letter from DHNI, came into operation in all parts of the UK on 19 December 2022 and have an expiry date of 31 January 2023.
SUMMARY
SSPs, made under the Human Medicines Regulations 2012, are an additional tool to manage and mitigate medicines shortages.
SSPs enable community pharmacists to supply specified medicines in accordance with a protocol rather than a prescription, without needing to seek authorisation from the prescriber – saving time for patients, pharmacists and prescribers.
DHSC has developed a further five SSPs in response to current concerns across the UK regarding the availability of antibiotic preparations required for the treatment of Group A Streptococcus infection.
These SSPs will allow community pharmacists to consider different oral antibiotic preparations to enable the continued supply of antibiotics to patients and mitigate the ongoing supply disruptions affecting phenoxymethylpenicillin.
For each SSP, DHSC has included specific patient counselling points which must be considered when deciding whether supply in accordance with an SSP is suitable for a patient.
Before supplying an alternative antibiotic, the pharmacist must firstly consider if a suitable supply can be made by using an alternative formulation of phenoxymethylpenicillin in accordance with the relevant SSP (SSP040 – SSP042). Where that is not possible, only specified antibiotics can be substituted for prescriptions for duration of no longer than 10 days, in order of preference depending on availability and the dosing needs for the patient (see specific SSP for details).
Full details on these SSPs are available on the dedicated page on the Business Services Organisation website HERE.
ACTION
Contractors are asked to:
Note the issue of five SSPs (SSP043 – SSP047) in response to current concerns across the UK regarding the availability of antibiotic preparations (in addition to the three SSPs (SSP040 – SSP042) issued on 15 December 2022).
Review theattached letterfrom DHNI detailing these five SSPs, ensure that they are familiar with the detail contained within each SSP, and to ensure that their dispensary teams are aware of these new protocols.
Note that the ‘Addendum – Supporting information on notifying other healthcare professionals’ does not apply in Northern Ireland. Pharmacists in Northern Ireland should refer to the existing SSP operational guidance on the BSO website HERE.
Note also the specific guidance on professional judgement and patient/carer consent detailed in the letter and in the operational guidance.
Contractors should contact their local SPPG office in the first instance should further information be required. CPNI colleagues are also available for assistance.
Kind regards
SENT ON BEHALF OF GERARD GREENE Chief Executive
This update contains important information for community pharmacy teams, including details of the ongoing response to the COVID-19 pandemic.
Please bring this to the attention of your pharmacy team(s).
Kind regards
SENT ON BEHALF OF DR. GARETH C. GILVARY Governance & Support Pharmacist
Dear Contractor,
CPNI attendees met with Mr Peter May, Permanent Secretary, DoH(NI) along with other SPPG and DoH(NI) officials on Wednesday 14 December 2022.
At the meeting Mr May, in listening to representations made by CPNI, gave a commitment that correspondence would be issued to CPNI no later than Monday 19 December 2022 containing a proposal, including financial aspects, for CPNI to consider in relation to current service and funding issues.
CPNI therefore expects to receive a proposal within the next working day or so. A meeting of CPNI Directors will be called on Monday as soon as is practicable after any proposal is received, with the decision of CPNI being conveyed to Contractors shortly thereafter.
For those Contractors who have been notified to provide Rota services over the Christmas and New Year holiday period your position of not being able to confirm rota service provision to SPPG is still applicable. I would ask that you share with CPNI offices info@communitypharmacyni.co.uk the details of the rota service that SPPG have asked you to provide.
Please do not hesitate to contact CPNI offices if you require any additional information.
Kind regards
SENT ON BEHALF OF GERARD GREENE Chief Executive
Dear Contractor
The Department of Health and Social Care (DHSC) has issued three Serious Shortage Protocols (SSPs) in response to current concerns across the UK regarding the availability of antibiotic preparations required for the treatment of Group A Streptococcus infection. These SSPs, which are detailed in the attached letter from DHNI, came into operation in all parts of the UK on 15 December 2022 and have an expiry date of 31 January 2023.
SUMMARY
SSPs made under the Human Medicines Regulations 2012 are an additional tool to manage and mitigate medicines shortages.
SSPs enable community pharmacists to supply specified medicines in accordance with a protocol rather than a prescription without needing to seek authorisation from the prescriber – saving time for patients, pharmacists and prescribers.
DHSC has developed SSPs for three phenoxymethylpenicillin products.
Full details on these SSPs are available on the dedicated page on the Business Services Organisation website HERE.
ACTION
Contractors are asked to:
Review the attached letter from DHNI detailing these SSPs and to ensure that their dispensary teams are aware of these new protocols.
Note that the ‘Addendum – Supporting information on notifying other healthcare professionals’ does not apply in Northern Ireland. Pharmacists in Northern Ireland should refer to the existing SSP operational guidance on the BSO website HERE.
Note also the specific guidance on professional judgement and patient/carer consent detailed in the letter and in the operational guidance.
Contractors should contact their local SPPG office in the first instance should further information be required. CPNI colleagues are also available for assistance.
Kind regards
SENT ON BEHALF OF GERARD GREENE Chief Executive
Dear Contractor
Northern Ireland’s Chief Medical Officer has issued correspondence advising on an updated drug safety alert regarding Valproate. The CMO’s letter is available here.
SUMMARY
The letter provides the following advice for healthcare professionals:
Continue to follow the existing strict precautions, including that valproate should not be prescribed to female children or women of childbearing potential unless other treatments are ineffective or not tolerated and that any use of valproate in women of childbearing potential who cannot be treated with other medicines is in accordance with the Pregnancy Prevention Programme
Following a new safety review conducted in light of concerns that the current regulatory requirements for safe use are not being consistently followed, the Commission on Human Medicines (CHM) has advised that there should be greater scrutiny of the way valproate is prescribed and that further risk minimisation measures are required – in particular that 2 specialists should independently consider and document that there is no other effective or tolerated treatment for patients aged under 55 years
Consider all other suitable therapeutic options before newly prescribing valproate in patients younger than 55 years
ACTION
Contractors are asked to:
Review the attached correspondence and ensure pharmacy teams are aware of the communication
Note that these new measures will be implemented over the coming months. In the meantime, GPs and pharmacists should continue to provide repeat prescriptions for valproate and dispensers should continue to ensure patients receive the patient card, a copy of the Patient Information Leaflet and packaging bearing pregnancy warnings
Note that patients currently taking valproate must be advised not to stop taking it unless they are advised by a specialist to do so
Further information on current safety measures for valproate due to risks with pregnancy exposure, safety review of data relating to valproate, CHM advice and recommended new measures, adherence to Pregnancy Prevention Programme requirements, and the use of valproate outside of the licenced indication, is available in the MHRA Drug Safety Update bulletin.
If you have any queries please do not hesitate to contact a member of the CPNI team.
Kind regards
SENT ON BEHALF OF GERARD GREENE Chief Executive
WhatsApp Business Terms of Service can be found here and privacy policy hereUCA-NI Privacy Policy We take your privacy seriously and do not share or sell any personal details with third parties for commercial purposes. If you have any questions, please contact the CPNI office. You can withdraw your consent to be contacted at any time by calling 028 9069 0444 or by emailing info@communitypharmacyni.co.uk. CPNI Data Protection Policy and Data Retention policy can be found Click Here
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
